GENE Genetic Technologies: שווי הפעילות העסקית

The price action of Genetic Technologies (GENE) reflects a business valuation that currently stands at . Genetic Technologies is expanding its B2B presence by promoting geneType IT solutions for the detection of cancer threats. The development of new multigene panels enables the continuous updating of the diagnostic portfolio. Modern centers in the US and Australia form the operational foundation, where scientific data is applied to preventive healthcare.

The high-tech capital of Genetic Technologies (GENE), based on genetic expertise and unique R&D, determines the intrinsic value of the business. By analyzing the historical enterprise value trend, an investor can identify the real acquisition price of the asset through the sum of market capitalization and net debt, allowing for an objective assessment of whether the company is overvalued or undervalued relative to its fundamental intellectual resources.